About Neoprobe
Neoprobe is a Healthcare company based in Cincinnati (United States) founded in 1996, and was acquired by Devicor Medical in May 2011. Gamma detection devices and radiopharmaceuticals for cancer are provided. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Pan Cancer. Its competitors include Insitro, BridgeBio and GRAIL; 3 of its 3 listed competitors have raised funding.
Company details
Neoprobe was founded in 1996 in Cincinnati, United States, within the medical devices and radiopharmaceuticals sector. Gamma detection devices are supplied to identify radiopharmaceuticals during cancer surgeries, with the system optimized for enhanced intra-operative precision. Two radiopharmaceutical agents are under development to support cancer detection and treatment. Operations focus on these technologies for oncology applications.
- Headquarters Cincinnati, United States
- Stage Acquired
- SectorsHealthcare
- Website neoprobe.com
- Social LinkedIn Facebook
- Acquired by Devicor Medical (May 2011)
- Latest Funding Round$10M (USD), Debt – Venture
Jan 2012
- InvestorsHHS
& 3 more
- Acquired byDevicor Medical
(May 2011)
Funding Insights of Neoprobe
- Total Rounds 7
- Last Round Debt – Venture — $10M
- First Round $2.8M
(Nov 2003)
- Investors Count 3
All 7 funding rounds of Neoprobe with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2012 | $10M | Debt – Venture | – | – | |
| Nov 2010 | $244,000 | Grant | – | – | |
| Jul 2010 | $14M | Post-IPO | – | – | – |
| Dec 2008 | $13M | Post-IPO | – | – | – |
| Jul 2007 | $1M | Post-IPO | – | – | – |
| Dec 2004 | $8.1M | Post-IPO | – | – | |
| Nov 2003 | $2.8M | Post-IPO | – | – | – |
4 investors in total: 4 institutional.
Investors in Neoprobe
Neoprobe has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Mammotome and Hercules Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| herculesfinance.com | ||||
Private equity firm focused on company buyouts | gppfunds.com | Greenwich, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Minimally invasive breast biopsy systems are developed for cancer sampling. | 1959 | mammotome.com | Cincinnati, United States |
Investor details for Neoprobe
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Neoprobe
4 dated milestones of Neoprobe across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Neoprobe is founded.
- Funding First funding round of $2.8M.
- Exit Acquired by Devicor Medical.
- Funding Latest funding round, Debt – Venture, of $10.0M.
Competitors of Neoprobe
Neoprobe has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and GRAIL.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. |
Detailed competitors of Neoprobe
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Neoprobe (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neoprobe
Complete news archive for Neoprobe
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neoprobe
Neoprobe was founded in 1996 and raised its 1st funding round 7 years after it was founded.
Neoprobe is headquartered in Cincinnati, United States. It is registered at Cincinnati, Ohio, United States.
Neoprobe was founded in 1996 in Cincinnati, United States, within the medical devices and radiopharmaceuticals sector. Gamma detection devices are supplied to identify radiopharmaceuticals during cancer surgeries, with the system optimized for enhanced intra-operative precision. Two radiopharmaceutical agents are under development to support cancer detection and treatment. Operations focus on these technologies for oncology applications.
Neoprobe has 4 investors. Key investors include HHS, Mammotome, Hercules Finance, and Great Point Partners.
Yes. Neoprobe was acquired by Devicor Medical in May 2011.